Literature DB >> 10909416

Mammalian heparanase as mediator of tumor metastasis and angiogenesis.

I Vlodavsky1, M Elkin, O Pappo, H Aingorn, R Atzmon, R Ishai-Michaeli, A Aviv, I Pecker, Y Friedmann.   

Abstract

Expression of heparan sulfate-degrading endoglycosidases, commonly referred to as heparanases, correlates with the metastatic potential of tumor cell lines, and treatment with heparanase inhibitors markedly reduces the incidence of metastasis in experimental animals. We purified a 50 kDa heparanase from human hepatoma and placenta and cloned a cDNA and gene encoding a protein of 543 amino acids. Only one heparanase sequence was identified, suggesting that this enzyme is the dominant endoglucuronidase in mammalian tissues. Expression of the cloned cDNA in insect and mammalian cells yielded 65 kDa and 50 kDa recombinant proteins. The 50 kDa enzyme represents an N-terminal processed enzyme that is at least 200-fold more active than the full-length 65 kDa form. Processing was demonstrated following incubation of the full-length recombinant enzyme with intact tumor cells. The heparanase mRNA and protein are preferentially expressed in metastatic cell lines and in specimens of human melanomas and carcinomas. In the colon, both the heparanase mRNA and protein are expressed already at the stage of tubulovillous adenoma, but not in the adjacent 'normal-looking' colon epithelium. Non-metastatic murine T lymphoma and melanoma cells transfected with the heparanase gene acquired a highly metastatic phenotype in vivo. Apart from its involvement in the egress of cells from the vasculature, heparanase is tightly involved in angiogenesis, both directly--by promoting invasion of endothelial cells (vascular sprouting), and indirectly--by releasing heparan sulfate-bound basic fibroblast growth factor, and generating HS degradation fragments that promote bFGF activity. The angiogenic potential of heparanase was demonstrated in vivo (Matrigel plug assay) by showing a three to fourfold increase in neovascularization induced by Eb T lymphoma cells following their transfection with the heparanase gene. The ability of heparanase to promote both tumor angiogenesis and metastasis makes it a promising target for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10909416

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  12 in total

1.  Heparan Sulfate Regrowth Profiles Under Laminar Shear Flow Following Enzymatic Degradation.

Authors:  Kristina M Giantsos-Adams; Andrew Jia-An Koo; Sukhyun Song; Jiro Sakai; Jagadish Sankaran; Jennifer H Shin; Guillermo Garcia-Cardena; C Forbes Dewey
Journal:  Cell Mol Bioeng       Date:  2013-02-20       Impact factor: 2.321

Review 2.  Aspirin acts in esophageal cancer: a brief review.

Authors:  Weiming Hao; Yaxing Shen; Mingxiang Feng; Hao Wang; Miao Lin; Yong Fang; Lijie Tan
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  Chemical Tumor Biology of Heparan Sulfate Proteoglycans.

Authors:  Karthik Raman; Balagurunathan Kuberan
Journal:  Curr Chem Biol       Date:  2010-01-01

4.  Expression of heparanase mRNA in anti-sense oligonucleotide-transfected human esophageal cancer EC9706 cells.

Authors:  Kui-Sheng Chen; Lan Zhang; Lin Tang; Yun-Han Zhang; Dong-Ling Gao; Liang Yan; Lei Zhang
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

5.  Transfection of antisense oligodeoxynucleotide inhibits heparanase gene expression and invasive ability of human pancreatic cancer cell in vitro.

Authors:  Jun Gao; Lin Su; Renyi Qin; Qing Chang; Tao Huang; Yanping Feng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

6.  Melanocyte transformation associated with substrate adhesion impediment.

Authors:  Sueli M Oba-Shinjo; Mariangela Correa; Tatiana I Ricca; Fernanda Molognoni; Maria A Pinhal; Izabel A Neves; Sueli K Marie; Lúcia O Sampaio; Helena B Nader; Roger Chammas; Miriam G Jasiulionis
Journal:  Neoplasia       Date:  2006-03       Impact factor: 5.715

7.  Tumor angiogenesis: insights and innovations.

Authors:  Fernando Nussenbaum; Ira M Herman
Journal:  J Oncol       Date:  2010-04-26       Impact factor: 4.375

8.  Contribution of eIF-4E inhibition to the expression and activity of heparanase in human colon adenocarcinoma cell line: LS-174T.

Authors:  Yu-Jie Yang; Ya-Li Zhang; Xu Li; Han-Lei Dan; Zhuo-Sheng Lai; Ji-De Wang; Qun-Ying Wang; Hai-Hong Cui; Yong Sun; Ya-Dong Wang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

9.  Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis.

Authors:  Thomas Kelly; Larry J Suva; Kristy M Nicks; Veronica MacLeod; Ralph D Sanderson
Journal:  J Bone Miner Res       Date:  2010-06       Impact factor: 6.741

10.  Heparanase, galectin-3, and tissue factor mRNA are expressed in benign neoplasms of the thyroid.

Authors:  Andreas E Buchs; Sergei Zehavi; Osnat Sher; Eyal Yeheskely; Michael Muggia-Sulam; Yoav Sherman; Micha J Rapoport
Journal:  Endocrine       Date:  2003-11       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.